Physician profile
Devika Brijlall
NPI 1811073182
$6,672.42
in general payments reported to CMS, 2019-2025
20 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,233 · 2022: $640 · 2023: $1,441 · 2024: $1,543 · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,799.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,425.26 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $901.97 | 2021-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $857.32 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $619.43 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $518.48 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $429.75 | 2023-2025 | Exalt Model D, General - Hemostasis |
| Exact Sciences Corporation | $312.48 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Biotech, INC. | $299.54 | 2025 | Tremfya |
| Genentech USA, INC. | $271.26 | 2021 | |
| Conmed Corporation | $217.44 | 2025 | Conmed Generators, Conmed Biliary |
| Celltrion USA INC. | $201.55 | 2024-2025 | Zymfentra, Vegzelma |
| Pulmonx Corporation | $123.76 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Novo Nordisk INC | $119.26 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $115.74 | 2021 | |
| Abbott Laboratories | $98.49 | 2025 | Freestyle Libre 3 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $45.48 | 2025 | Pancreaze |
| Intercept Pharmaceuticals, INC. | $41.15 | 2023-2025 | Ocaliva |
| Celgene Corporation | $30.54 | 2021-2023 | Zeposia |
| Medtronic, INC. | $22.70 | 2023 | Sinuva |
| Amgen INC. | $20.82 | 2023 | Avsola, Amjevita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devika Brijlall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.